Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 50 条

[31] Risk prediction in early triple negative breast cancer
Mason, Sofia
BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
[32] Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, Peter
Cortes, Javier
Pusztai, Lajos
McArthur, Heather
Kuemmel, Sherko
Bergh, Jonas
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Foukakis, Theodoros
Fasching, Peter A.
Cardoso, Fatima
Untch, Michael
Jia, Liyi
Karantza, Vassiliki
Zhao, Jing
Aktan, Gursel
Dent, Rebecca
O'Shaughnessy, Joyce
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 810 - 821
[33] Neoadjuvant eribulin in early triple negative breast cancer
Naito, Y.
Yonemori, K.
Yamamoto, H.
Takahashi, M.
Nakamura, R.
Masuda, N.
Aogi, K.
Yamanaka, T.
Ito, Y.
Yoshida, A.
Tsuda, H.
Kuchiba, A.
Hata, T.
Tamura, K.
Fujiwara, Y.
EUROPEAN JOURNAL OF CANCER, 2018, 92 : S97 - S98
[34] Pembrolizumab for Early Triple-Negative Breast Cancer
Cetin, Bulent
Gumusay, Ozge
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (26):
[35] Update on triple-negative breast cancers - highlighting subtyping update and treatment implication
Tsang, Julia Y.
Tse, Gary M.
HISTOPATHOLOGY, 2023, 82 (01) : 17 - 35
[36] Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline
Alonso-Ron, Carlos
Vethencourt, Andrea
Gonzalez-Suarez, Eva
Oruezabal, Roke Inaki
CANCERS, 2025, 17 (04)
[37] Update on triple-negative breast cancer: prognosis and management strategies
Brouckaert, Olivier
Wildiers, Hans
Floris, Giuseppe
Neven, Patrick
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2012, 4 : 511 - 520
[38] Diagnostics and systemic treatment of triple-negative breast cancer: discoveries of the past, challenges for the future
Chmielewski, Grzegorz
Gozdz, Stanislaw
MEDICAL STUDIES-STUDIA MEDYCZNE, 2024, 40 (01) : 75 - 81
[39] Update on immuno-oncology in triple-negative breast cancer
Heimes, Anne-Sophie
Schmidt, Marcus
GYNAKOLOGE, 2021, 54 (08): : 590 - 595
[40] Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
Amos, Keith D.
Adamo, Barbara
Anders, Carey K.
INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012

← 1 2 3 4 5 →